Chicago Tribune reported how Tempus achieved ‘unicorn’ status by receiving $80 million in new funding. Based in Chicago, Tempus is a biotechnology company that utilizes data to tailor cancer care and therapy. With a shared goal of improving patient outcomes, the technology company is building a large network of molecular and clinical data with an operating system to make the data accessible and more efficient.
Eric Lefkofsky, co-founder of Groupon, leads the 400-person company that is rapidly growing. Averaging 30 new employees a month, Lefkofsky confirms that a portion of the funding will go towards new hires.
Tempus is discovering trends in cancer treatment through collecting data from patients going through treatment. Some of the data collection, Lefkofsky shares, is even digitalizing doctor’s notes to collect and expand for further research. Tempus has networked with various types of organizations within the health field such as doctors and drug companies with the mission to utilize big data to the benefit and efficiency of cancer patient care.
Since establishing Tempus in 2015, Lefkofsky has received $210 million in investments for the company. With the most recent add to the company’s funding, Tempus has reached a total of $1.1 billion in funding which very few start-ups have experienced. Investors in the most recent round of $80 million are both old and new investors. Contributors include New Enterprise Associates, Kinship Trust Co., and Revolution Growth.
Lefkofsky is an Entrepreneur and Philanthropist, who a co0founder of Lightbank, Uptake Technologies, Meidaocean, Innerworkings and Echo Global Logistics. He earned his Bachelors from the University of Michigan and Juris Doctorate from University of Michigan Law School. He also established the Lefkofsky Family Foundation in 2006, a private charitable foundation with the aim to enhance lives in local communities. He is also extremely involved in the Chicago community serving as Trustee and Chairman for numerous Chicago organizations.